Pioglitazone prevents diabetes in impaired glucose tolerance

Pioglitazone taken prophylactically provided marked protection against the onset of type 2 diabetes in persons at high risk of the disease. In a double-blind study, 602 subjects with impaired glucose tolerance and a body mass index of 25 kg/m2 or greater were randomized to pioglitazone (30 mg/day for the first month, increased to 45 mg/day thereafter) or placebo. After a median of 2.4 years, the annual average incidence of diabetes was 2.1% in patients assigned to pioglitazone and 7.6% in those assigned to placebo, corresponding to a 72% reduction in conversion to type 2 diabetes in the pioglitazone group. Pioglitazone recipients also experienced a 31% decline carotid intima-media thickness. Weight gain and edema were the major side effects of pioglitazone.

Related Videos
Jolie Apicella, JD
Jolie Apicella, JD
Jolie Apicella, JD
Jolie Apicella, JD
Jolie Apicella, JD
Jolie Apicella, JD
Jolie Apicella, JD
Jolie Apicella, JD
Beth Lown, MD
© 2023 MJH Life Sciences

All rights reserved.